Immunocore Holdings (IMCR) Total Current Liabilities (2019 - 2026)

Immunocore Holdings (IMCR) has reported Total Current Liabilities for 8 consecutive years, with $240.1 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 60.97% year-over-year to $240.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $240.1 million (up 60.97% YoY) and the FY2025 annual result came in at $246.7 million, up 16.27% from the prior year.
• Total Current Liabilities declined to $240.1 million in Q1 2026 per IMCR's latest filing, from $246.7 million in the prior quarter.
• Over the last five years, Total Current Liabilities for IMCR reached as high as $266.2 million in Q3 2024 and fell as low as $91.0 million in Q3 2022.
• A 5-year average of $172.2 million and a median of $170.1 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2025 — Total Current Liabilities slumped 36.02% — and 2026, when it soared 60.97%.
• Year by year, Total Current Liabilities stood at $97.5 million in 2022, then soared by 42.65% to $139.0 million in 2023, then soared by 52.63% to $212.2 million in 2024, then grew by 16.27% to $246.7 million in 2025, then dropped by 2.67% to $240.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $240.1 million, $246.7 million, and $170.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.